Skip to main content
SpringerLink
Log in

Carfilzomib/dexamethasone/rituximab

Various toxicities: 6 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Chaudhry M, et al. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenstrom's macroglobulinemia. Leukemia and Lymphoma 60: 964-970, No. 4, 21 Mar 2019. Available from: URL: http://doi.org/10.1080/10428194.2018.1508668 - USA

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carfilzomib/dexamethasone/rituximab. Reactions Weekly 1753, 95 (2019). https://doi.org/10.1007/s40278-019-61987-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-61987-0

Search

Navigation